[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100625000":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":34,"centralContacts":39,"locations":49,"responsibleParty":70,"collaborators":10,"id":72,"slug":73,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":80,"sex":81,"minAge":82,"maxAge":10,"enrollmentInfo":83,"targetDuration":10,"studyType":86,"phases":10,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":98,"whyStopped":10,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"Mario Negri Institute for Pharmacological Research","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Sera samples of RTX-resistant patients",null,"30 RTX-resistant patients (randomly selected among those with serum samples available)",[13],"Genetic: Multi-omics Analysis",{"label":15,"type":10,"description":16,"interventionNames":17},"Healthy volunteers","Healthy, age- and sex-matched subjects will be analysed as controls.",[13,18],"Procedure: Sample collection",{"label":20,"type":10,"description":21,"interventionNames":22},"Sera samples of RTX-responsive MN patients","30 RTX-responsive MN patients (matched for age, sex, baseline eGFR and proteinuria, and comorbidities with RTX-resistant MN)",[13],[24,29],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":10},"GENETIC","Multi-omics Analysis","High-level molecular profiling (pharmacogenetics, proteomics, metabolomics, and scRNAseq) on patient samples",[15,9,20],{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":10},"PROCEDURE","Sample collection","One single blood sample of approximately 25 ml.",[15],[35],{"name":36,"affiliation":37,"role":38},"Giuseppe Remuzzi, M.D.","Istituto Di Ricerche Farmacologiche Mario Negri","STUDY_DIRECTOR",[40,45],{"name":41,"role":42,"phone":43,"phoneExt":10,"email":44},"Marina Noris, Ph.D.","CONTACT","+390354535362","marina.noris@marionegri.it",{"name":46,"role":42,"phone":47,"phoneExt":10,"email":48},"Matias Trillini, M.D.","+390354535411","matias.trillini@marionegri.it",[50],{"facility":51,"status":10,"city":52,"state":53,"zip":54,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"Clinical Research Centre for Rare Diseases Aldo e Cele Daccò","Ranica","BG","24020","Italy","IT",{"type":58,"coordinates":59},"Point",[60,61],9.71335,45.72328,{"lat":61,"lon":60},[64,66,68],{"name":65,"role":42,"phone":47,"phoneExt":10,"email":48},"Matias Trillini, MD",{"name":46,"role":67,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"name":69,"role":67,"phone":10,"phoneExt":10,"email":10},"Marina Noris, PhD",{"type":71,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100625000","omics-of-rituximab-resistance-100625000",false,"NCT07416942","Omics of Rituximab-resistance","Identification of a Pharmacogenomic Signature for Anti-B Cell Precision Therapy in Membranous Nephropathy","CONFUCIUS","Patients\n\nInclusion Criteria:\n\n* Adult patients\n* Biopsy-proven primary membranous nephropathy (MN)\n* Written informed consent for storage of biological samples in the local biobank\n\nExclusion Criteria:\n\n* Absence of signed written informed consent for the storage of samples in the biobank\n\nHealthy subjects\n\nInclusion Criteria:\n\n* Adult male and female\n* Written informed consent\n\nExclusion Criteria:\n\n* History of renal diseases, autoimmune disorders, diabetes mellitus, current allergies\n* Subjects who have taken antibiotics, anti-inflammatory drugs, or antihistamines within the past 7 days",true,"ALL","18 Years",{"count":84,"type":85},120,"ESTIMATED","OBSERVATIONAL","The CONFUCIUS project aims to establish a personalised medicine framework for MN patients by integrating pharmacogenomics with other -omics technologies in order to identify biomarkers that predict response to RTX, ultimately enabling optimized treatment selection. Using a multiomics approach, we will analyse genetic variants, serum and kidney proteomics, and serum metabolomics profiles from a well-characterised retrospective cohort of MN patients to uncover predictive biomarkers of RTX response.\n\nThis is a non-pharmacological interventional study, conducted on biological samples from patients stored in the local biobank and on samples from healthy volunteers, which will be collected and subsequently stored in the biobank.",[89],"Membranous Nephropathy",[91,92,93,94,95,96,97],"membranous nephropathy","rituximab","B cells","pharmacogenetics","proteomics","metabolomics","scRNAseq","NOT_YET_RECRUITING","2026-02-10",{"date":101,"type":102},"2026-02-18","ACTUAL",{"date":104,"type":85},"2026-04",{"date":106,"type":85},"2029-03",{"name":5,"class":6},1]